Olokizumab

Phase 3Monoclonal antibody

UCB

Olokizumab is one of 115 small molecule programs targeting Polymyalgia Rheumatica. It is currently in Phase 3.

Indications

Total Trials

Active Trials

114

Competitors

Pipeline

Status by Indication[3][1]

Indication

Polymyalgia RheumaticaActive, not recruiting

Severe Acute Respiratory SyndromeActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

COVID-19Active, not recruiting

Polymyalgia RheumaticaPhase 3

Active, not recruiting

Severe Acute Respiratory SyndromePhase 2/Phase 3

Active, not recruiting

Rheumatoid ArthritisPhase 2

Active, not recruiting

COVID-19Preclinical

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Olokizumab

UCB

Phase 3

1 2

Bnt162b2

BioNTech

Preclinical

29 3

Tricor

JJagotec

Preclinical

1 4

Statin

Bristol-Myers Squibb

Preclinical

1 5

Piperacillin/tazobactam

Pfizer

Preclinical

1 6

Glucocorticoid

AbbVie

Preclinical

1 7

HB-Admscs

HHope Biosciences Research Foundation

Preclinical

4 8

Aprotinin

Bayer

Preclinical

1 9

Blood Taken

HHospices Civils de Lyon

Preclinical

1 10

Selenium

SSWOG Cancer Research Network

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Rheumatoid Arthritis4 trials

Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease

Completed·UUnknown Sponsor·Phase 3·NCT02760368·428 enrolled

Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4

Completed·UUnknown Sponsor·Phase 1·NCT04246762·17 enrolled

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease

Completed·UUnknown Sponsor·Phase 3·NCT02760433·368 enrolled

Show 1 more trial

Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

Completed· UCB logo

UCB·Phase 2·NCT01463059·119 enrolled

Severe Acute Respiratory Syndrome2 trials

Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)

Completed·UUnknown Sponsor·Phase 2/3·NCT04380519·372 enrolled

Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19).

Withdrawn·RR-Pharm·Phase 2/3·NCT04452474

COVID-191 trial

Study of the Outcomes of Olokizumab Therapy in Hospitalized Patients With SARS-CoV-2 (COVID-19) Infection

Completed·RR-Pharm··NCT05196477·3,087 enrolled

Treatment1 trial

Study of Efficacy of Different Treatment Regimens of Olokizumab

Unknown status·RR-Pharm·Phase 3·NCT05187793·198 enrolled

Efficacy and Safety1 trial

A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's Disease

Withdrawn· UCB logo

UCB·Phase 2·NCT01635621

1 more indication

Polymyalgia Rheumatica1 trial

An International, Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Efficacy and Safety of Olokizumab in Patients With Polymyalgia Rheumatica

Active, not recruiting·RR-Pharm·Phase 3·NCT07670546·125 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Olokizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Olokizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Olokizumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — UCB company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: UCB

Olokizumab

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Rheumatoid Arthritis4 trials

Severe Acute Respiratory Syndrome2 trials

COVID-191 trial

Treatment1 trial

Efficacy and Safety1 trial

Polymyalgia Rheumatica1 trial

References

Drug Info

Quick Facts

Related News